ArticleOncogene2004
Enhanced malignant tumorigenesis in Cdk4 transgenic mice.
Article in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 59 citations in OpenAlex.
- Luteoloside Induces G0/G1 Phase Arrest of Neuroblastoma Cells by Targeting p38 MAPK.Molecules (Basel, Switzerland) · 2023Article
- Cyclin-dependent kinase 4 expression alters the number of keratinocyte stem cells in the mouse hair follicle.Cell biology international · 2022Article
- CDK4 has the ability to regulate Aurora B and Cenpp expression in mouse keratinocytes.Oncology letters · 2021Article
- Characterization of hair-follicle side population cells in mouse epidermis and skin tumors.Oncology letters · 2017Article
- Cyclin D3 deficiency inhibits skin tumor development, but does not affect normal keratinocyte proliferation.Oncology letters · 2017Article
- CDK4 in lung, and head and neck cancers in old age: evaluation as a biomarker.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017Article
- Cell cycle proteins as promising targets in cancer therapy.Nature reviews. Cancer · 2017Review
- PKK suppresses tumor growth and is decreased in squamous cell carcinoma of the skin.The Journal of investigative dermatology · 2015Article
- Article
- Knocking down CDK4 mediates the elevation of let-7c suppressing cell growth in nasopharyngeal carcinoma.BMC cancer · 2014Article
- Article
- Immunohistochemical characterization of cyclin dependent kinase-4 in different histological grades of oral leukoplakia and oral squamous cell carcinoma.Journal of oral and maxillofacial pathology : JOMFP · 2014Article
- Skin Tumors Rb(eing) Uncovered.Frontiers in oncology · 2013Review
- Skp2 deficiency inhibits chemical skin tumorigenesis independent of p27(Kip1) accumulation.The American journal of pathology · 2013Article
- Disrupting the PIKE-A/Akt interaction inhibits glioblastoma cell survival, migration, invasion and colony formation.Oncogene · 2013Article
- Drosophila cyclin D/Cdk4 regulates mitochondrial biogenesis and aging and sensitizes animals to hypoxic stress.Cell cycle (Georgetown, Tex.) · 2012Article
- Combined effect of cyclin D3 expression and abrogation of cyclin D1 prevent mouse skin tumor development.Cell cycle (Georgetown, Tex.) · 2012Article
- Skp2 is necessary for Myc-induced keratinocyte proliferation but dispensable for Myc oncogenic activity in the oral epithelium.The American journal of pathology · 2011Article
- Cdk2-null mice are resistant to ErbB-2-induced mammary tumorigenesis.Neoplasia (New York, N.Y.) · 2011Article
- Elevated expression of CDK4 in lung cancer.Journal of translational medicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
In a previous study, we reported that overexpression of cyclin-dependent kinase-4 (CDK4) in mouse epidermis results in epidermal hyperplasia, hypertrophy and severe dermal fibrosis. In this study, we have investigated the susceptibility to skin tumor formation by forced expression of CDK4. Skin tumors from transgenic mice showed a dramatic increase in the rate of malignant progression to squamous cell carcinomas (SCC) in an initiation-promotion protocol. Histopathological analysis of papillomas from transgenic mice showed an elevated number of premalignant lesions characterized by dysplasia and marked atypia. Interestingly, transgenic mice also developed tumors in initiated but not promoted skin, demonstrating that CDK4 replaced the action of tumor promoters. These results suggest that expression of cyclin D1 upon ras activation synergizes with CDK4 overexpression. However, cyclin D1 transgenic mice and double transgenic mice for cyclin D1 and CDK4 did not show increased malignant progression in comparison to CDK4 transgenic mice. Biochemical analysis of tumors showed that CDK4 sequesters the CDK2 inhibitors p27Kip1 and p21Cip1, suggesting that indirect activation of CDK2 plays an important role in tumor development. These results indicate that, contrary to the general assumption, the catalytic subunit, CDK4, has higher oncogenic activity than cyclin D1, revealing a potential use of CDK4 as therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.